Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.23 +1.7%	$6.30	$3.93 ▼ $7.54	$364.59M	1.55	710,270 shs	850,820 shs
BNTC Benitec Biopharma	$12.99 +2.3%	$12.58	$8.06 ▼ $17.15	$333.38M	0.4	42,222 shs	74,167 shs
BYSI BeyondSpring	$1.76	$2.23	$0.98 ▼ $3.44	$70.99M	0.26	27,658 shs	26,529 shs
CGC Canopy Growth	$1.27 +2.4%	$1.22	$0.77 ▼ $6.30	$297.41M	0.67	22.15 million shs	17.13 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+1.69%	+1.40%	+7.75%	+12.62%	+37.98%
BNTC Benitec Biopharma	+2.28%	-0.15%	+9.62%	-1.52%	+44.98%
BYSI BeyondSpring	0.00%	-12.87%	-5.88%	+1.79%	-6.88%
CGC Canopy Growth	+2.42%	-2.31%	+8.55%	-30.60%	-80.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.4435 of 5 stars	3.5	2.0	0.0	4.5	2.5	2.5	1.3
BNTC Benitec Biopharma	1.3659 of 5 stars	3.6	1.0	0.0	0.0	1.3	0.8	0.0
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	0.7777 of 5 stars	0.0	2.0	0.0	0.0	3.3	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	169.71% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	100.15% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
CGC Canopy Growth	1.33	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BYSI, ABEO, CGC, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
8/12/2025	CGC Canopy Growth	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	105.93	N/A	N/A	$3.19 per share	2.27
BNTC Benitec Biopharma	$80K	4,262.34	N/A	N/A	$4.68 per share	2.78
BYSI BeyondSpring	$1.75M	40.56	N/A	N/A	($0.44) per share	-4.00
CGC Canopy Growth	$274.92M	1.11	N/A	N/A	$1.47 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	10.33	N/A	N/A	N/A	89.05%	45.64%	N/A
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
CGC Canopy Growth	-$429.86M	-$3.03	N/A	N/A	N/A	-155.76%	-89.93%	-44.24%	N/A

Latest BYSI, ABEO, CGC, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/8/2025	Q1 2026	CGC Canopy Growth	-$0.15	-$0.14	+$0.01	-$0.16	$64.98 million	$52.98 million
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.09	6.73	4.90
BNTC Benitec Biopharma	0.01	14.80	14.80
BYSI BeyondSpring	N/A	2.19	2.19
CGC Canopy Growth	0.59	3.07	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
BNTC Benitec Biopharma	52.19%
BYSI BeyondSpring	40.29%
CGC Canopy Growth	3.33%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
BNTC Benitec Biopharma	1.30%
BYSI BeyondSpring	29.31%
CGC Canopy Growth	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.28 million	47.74 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
CGC Canopy Growth	3,150	239.85 million	239.47 million	Optionable

BYSI, ABEO, CGC, and BNTC Headlines

Recent News About These Companies

3 Cannabis Stocks to Watch After Trump's Marijuana Rescheduling Signal

August 22 at 10:36 AM | zacks.com

Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market

August 18, 2025 | prnewswire.com

Virtu Financial LLC Invests $255,000 in Canopy Growth Corporation (NASDAQ:CGC)

August 18, 2025 | marketbeat.com

Best Canadian Cannabis Stocks in 2025

August 17, 2025 | marijuanastocks.comM

Canopy Growth (NASDAQ:CGC) Stock Rating Upgraded by Zacks Research

August 17, 2025 | marketbeat.com

Marathon Trading Investment Management LLC Takes $276,000 Position in Canopy Growth Corporation (NASDAQ:CGC)

August 17, 2025 | marketbeat.com

Atb Cap Markets Predicts Stronger Earnings for Canopy Growth

August 15, 2025 | marketbeat.com

Canopy Growth Announces Mailing and Filing of Proxy Materials for Annual General and Special Meeting and Urges All Shareholders to Vote Now

August 15, 2025 | businesswire.com

Here is What to Know Beyond Why Canopy Growth Corporation (CGC) is a Trending Stock

August 14, 2025 | zacks.com

Canopy Growth (CGC) Q1 Revenue Jumps 9%

August 13, 2025 | theglobeandmail.com

Canopy Growth Corporation (NASDAQ:CGC) Q1 2026 Earnings Call Transcript

August 12, 2025 | msn.com

Best Cannabis Stocks To Add to Your Watchlist - August 11th

August 12, 2025 | marketbeat.com

Investors Buy Large Volume of Call Options on Canopy Growth (NASDAQ:CGC)

August 12, 2025 | marketbeat.com

Investors Buy High Volume of Canopy Growth Call Options (NASDAQ:CGC)

August 12, 2025 | americanbankingnews.com

Cannabis stocks surge as Trump consider reclassifying the drug

August 11, 2025 | proactiveinvestors.com

Canopy Growth Rallies On News Of Possible Rescheduling From Trump

August 11, 2025 | seekingalpha.com

Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification

August 11, 2025 | cnbc.com

Canopy Growth (NASDAQ:CGC) Releases Earnings Results, Beats Estimates By $0.01 EPS

August 11, 2025 | marketbeat.com

Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

A Preview Of Canopy Growth's Earnings

August 8, 2025 | benzinga.com

Canopy Growth posts Q1 beat thanks to strong cannabis sales

August 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, ABEO, CGC, and BNTC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$7.23 +0.12 (+1.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.21 -0.02 (-0.28%)

As of 08/22/2025 07:53 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Benitec Biopharma NASDAQ:BNTC

$12.99 +0.29 (+2.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.98 -0.01 (-0.08%)

As of 08/22/2025 04:04 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BeyondSpring NASDAQ:BYSI

$1.76 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.85%)

As of 08/22/2025 07:59 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Canopy Growth NASDAQ:CGC

$1.27 +0.03 (+2.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.03 (+2.76%)

As of 08/22/2025 08:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time